CK1epsilon (R178C)

CSNK1E · Variant type: point · HGVS: p.R178C

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gedatolisib	68.6%	31.4%	99.75
2	Neratinib	57.4%	42.6%	93.18
3	Sunitinib	54.9%	45.1%	91.73
4	Umbralisib	48.3%	51.7%	98.74
5	Bosutinib	46.7%	53.3%	87.22
6	Tivozanib	44.4%	55.6%	92.42
7	Pirtobrutinib	32.6%	67.4%	99.49
8	Ibrutinib	32.0%	68.0%	94.74
9	Futibatinib	24.9%	75.1%	98.48
10	Vemurafenib	16.5%	83.5%	96.49
11	Lazertinib	15.5%	84.5%	97.47
12	Dacomitinib	15.0%	85.0%	97.99
13	Defactinib	14.8%	85.2%	92.68
14	Erdafitinib	14.3%	85.7%	95.71
15	Capmatinib	12.9%	87.1%	99.75
16	Leniolisib	11.3%	88.7%	100.00
17	Lenvatinib	11.0%	89.0%	97.74
18	Afatinib	10.4%	89.6%	98.50
19	Selpercatinib	10.3%	89.8%	96.72
20	Temsirolimus	9.4%	90.6%	100.00
21	Dasatinib	9.1%	90.9%	87.97
22	Dabrafenib	8.4%	91.6%	94.74
23	Encorafenib	8.1%	91.9%	98.50
24	Fedratinib	7.8%	92.2%	96.21
25	Deucravacitinib	7.8%	92.2%	98.99

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gedatolisib	68.6%	—	—
Neratinib	57.4%	—	—
Sunitinib	54.9%	—	—
Umbralisib	48.3%	—	—
Bosutinib	46.7%	—	—
Tivozanib	44.4%	—	—
Pirtobrutinib	32.6%	—	—
Ibrutinib	32.0%	—	—
Futibatinib	24.9%	—	—
Vemurafenib	16.5%	—	—
Lazertinib	15.5%	—	—
Dacomitinib	15.0%	—	—
Defactinib	14.8%	—	—
Erdafitinib	14.3%	—	—
Capmatinib	12.9%	—	—
Leniolisib	11.3%	—	—
Lenvatinib	11.0%	—	—
Afatinib	10.4%	—	—
Selpercatinib	10.3%	—	—
Temsirolimus	9.4%	—	—
Dasatinib	9.1%	—	—
Dabrafenib	8.4%	—	—
Encorafenib	8.1%	—	—
Fedratinib	7.8%	—	—
Deucravacitinib	7.8%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.1ms